Paradigm Biopharmaceuticals Limited (ASX:PAR) Insider Acquires A$20,108.30 in Stock

Paradigm Biopharmaceuticals Limited (ASX:PARGet Free Report) insider Paul Rennie acquired 95,300 shares of the stock in a transaction dated Tuesday, October 15th. The shares were bought at an average cost of A$0.21 ($0.14) per share, with a total value of A$20,108.30 ($13,405.53).

Paradigm Biopharmaceuticals Price Performance

The company has a current ratio of 7.22, a quick ratio of 5.93 and a debt-to-equity ratio of 1.00.

Paradigm Biopharmaceuticals Company Profile

(Get Free Report)

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases.

Read More

Receive News & Ratings for Paradigm Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paradigm Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.